Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)
Experts applaud Amylyx for keeping its promise to withdraw ALS drug Relyvrio after trial failure
When Amylyx brought its ALS drug before the FDA in 2022, the biotech faced questions about what it would do if a crucial Phase 3 trial failed.
On Thursday, the company announced that it would pull the drug from the market less than a month after it failed to show that it slowed the disease better than a placebo. It’s a blow to Amylyx, which will let go about 70% of its workforce, but the move is earning praise for following through on its promise from 2022 that it would do “what’s right for patients,” as co-CEO Justin Klee pledged at the time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
